Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses

Reuters

Oct 30

Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses

Overview

Rafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expenses
Company's Q4 revenue was $350,000
Research and development expenses rose significantly due to Cyclo acquisition

Outlook

Rafael Holdings continues Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1

Result Drivers

ACQUISITION IMPACT - Consolidation of Cyclo Therapeutics' expenses contributed to increased R&D and administrative costs, widening net loss
FINANCIAL POSITION - $25 mln rights offering closed in June bolstered financial position for advancing Trappsol Cyclo program
R&D EXPENSES - R&D expenses rose to $7.5 mln in Q4 due to Cyclo acquisition and related activities

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		$350,000
Q4 Net Income		-$12.05 mln
Q4 Operating Income		-$12.76 mln

Press Release: ID:nGNX6YltrT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579139512"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579139512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579139512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 04:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579139512","market":"us","top_or_hot":-1,"title":"Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Rafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expenses</p></li><li><p>Company's Q4 revenue was $350,000</p></li><li><p>Research and development expenses rose significantly due to Cyclo acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rafael Holdings continues Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Consolidation of <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>' expenses contributed to increased R&amp;D and administrative costs, widening net loss</p></li><li><p>FINANCIAL POSITION - $25 mln rights offering closed in June bolstered financial position for advancing Trappsol Cyclo program</p></li><li><p>R&amp;D EXPENSES - R&amp;D expenses rose to $7.5 mln in Q4 due to Cyclo acquisition and related activities</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$350,000</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$12.05 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$12.76 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6YltrT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 04:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expenses</title></head><body><p><span>Overview</span></p><ul><li><p>Rafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expenses</p></li><li><p>Company's Q4 revenue was $350,000</p></li><li><p>Research and development expenses rose significantly due to Cyclo acquisition</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rafael Holdings continues Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ACQUISITION IMPACT - Consolidation of <a href=\"https://laohu8.com/S/CYTH\">Cyclo Therapeutics</a>' expenses contributed to increased R&amp;D and administrative costs, widening net loss</p></li><li><p>FINANCIAL POSITION - $25 mln rights offering closed in June bolstered financial position for advancing Trappsol Cyclo program</p></li><li><p>R&amp;D EXPENSES - R&amp;D expenses rose to $7.5 mln in Q4 due to Cyclo acquisition and related activities</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>$350,000</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$12.05 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>-$12.76 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX6YltrT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4205","symbol_name":"房地产经营公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nL1N3WA1N3:1","article_id":"2579139512","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579139512","pubTimestamp":1761770020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expensesOverviewRafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expensesCompany's Q4 revenue was $350,000Rese","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4205":"房地产经营公司","BK4007":"制药","BK4233":"房地产运营公司","RFL":"Rafael Holdings, Inc."},"translate_title":"Rafael Holdings第四季度净亏损因Cyclo收购相关费用扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RFL":0.9},"content_text":"Rafael Holdings Q4 net loss widens on Cyclo acquisition-related expensesOverviewRafael Holdings Q4 net loss widens to $12.1 mln due to acquisition-related expensesCompany's Q4 revenue was $350,000Research and development expenses rose significantly due to Cyclo acquisitionOutlookRafael Holdings continues Phase 3 trial for Trappsol® Cyclo™ in Niemann-Pick Disease Type C1Result DriversACQUISITION IMPACT - Consolidation of Cyclo Therapeutics' expenses contributed to increased R&D and administrative costs, widening net lossFINANCIAL POSITION - $25 mln rights offering closed in June bolstered financial position for advancing Trappsol Cyclo programR&D EXPENSES - R&D expenses rose to $7.5 mln in Q4 due to Cyclo acquisition and related activitiesKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Revenue$350,000Q4 Net Income-$12.05 mlnQ4 Operating Income-$12.76 mlnPress Release: ID:nGNX6YltrTFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}